Does Intravenous Acetaminophen Improve Postoperative Pain Control after Laparoscopic Appendectomy for Perforated Appendicitis? A Prospective Randomized Trial

Richard Sola Jr.1 Amita A. Desai1 Katherine W. Gonzalez1 Nichole M. Doyle2 Katrina L. Weaver1 Ashwini S. Poola1 Jason D. Fraser1 Shawn D. St. Peter1 Daniel L. Millspaugh2

1 Department of Surgery, Children’s Mercy Hospitals and Clinics, Kansas City, Missouri, United States
2 Department of Anesthesiology, Children’s Mercy Hospitals and Clinics, Kansas City, Missouri, United States


Abstract

Introduction The recent increased awareness of the dangers of opioids in the United States has highlighted the need to minimize narcotics and identify nonopioid options for pain control after surgery. With evidence suggesting that intravenous acetaminophen (IVA) can be an opioid sparing option, we conducted a prospective, randomized trial that evaluated the effect of IVA on the postoperative pain course of children with perforated appendicitis.

Materials and Methods After IRB approval, children with perforated appendicitis were randomized to receive postoperative IVA with the standard patient/nurse-controlled analgesia (PCA) or to receive the PCA alone. All patients were treated according to an evidence-based treatment protocol. The primary outcome was duration of time on PCA.

Results Eighty-two patients were analyzed from 7/14 to 11/15. There was no statistically significant difference in the time to transition from the PCA to oral pain medications for children given IVA compared with children not receiving IVA (76.4 ± 32.5 versus 86.7 ± 49.3 hours; p = 0.73). Children in the IVA group had no statistically significant difference in intravenous narcotics delivered and pain scores compared with the non-IVA group. There was no significant difference in the amount of oral narcotics between both groups (2.8 ± 2.4 versus 2.9 ± 2.5; p = 0.88). Patients who received IVA had higher medication charges ($3752.7 ± 1618.3 vs. $1198.19 ± 521.51; p < 0.01), but not total hospital charges ($53842.0 ± 19409.2 vs. $50501.03 ± 16223.32; p = 0.76).

Conclusion Children given IVA showed no difference in the transition time off the PCA and to oral pain medications after laparoscopic appendectomy for perforated appendicitis.

Keywords
► appendicitis
► acetaminophen
► children
► appendectomy
► pain

received July 18, 2017 accepted after revision November 14, 2017 published online January 2, 2018

© 2019 Georg Thieme Verlag KG Stuttgart - New York

ISSN 0939-7248.
Introduction

Acute appendicitis remains the most common inpatient abdominal pathology and an appendectomy is the most common abdominal surgery in children. Approximately 25 to 38% are found to have perforated appendicitis. Those with perforated appendicitis have higher morbidity rates especially higher rates of postoperative infection and longer hospital stays compared with those undergoing appendectomy for uncomplicated appendicitis.

Managing postoperative pain with perforated appendicitis can be a challenge. Evidence has shown that 32% have significant pain on the day of surgery and 18% will continue to have significant pain over the course of their hospital stay. Narcotics come with known adverse effects and risks. Numerous publications have investigated means to minimize narcotic burdens for children after surgery. We know that a previous retrospective review on the use of a multimodal analgesic regimen after laparoscopic appendectomy documented a reduction in postoperative pain. Yet, there is no prospective randomized trial evaluating multimodal analgesic therapy for children after appendectomy.

The objective of this study is to delineate the impact of intravenous acetaminophen (IVA) on the postoperative course of children who undergo laparoscopic appendectomy for perforated appendicitis. Our primary outcome was time to transition off patient/nurse-controlled analgesia (PCA) to oral pain medications. Our main secondary outcomes include amount of narcotic medication given and pain scores.

Materials and Methods

Approval was obtained from the Institutional Review Board (IRB# 13100328) prior to enrolling patients in this study. Children were subsequently enrolled after obtaining informed permission from the legal guardian. Patient’s signed assent was waived as all patients included were in pain and under the influence of pain medications due to perforated appendicitis. The enrollment process occurred after confirmation of perforated appendicitis either preoperatively by imaging or intraoperatively. The permission forms and consent process were audited by the IRB on a continuing basis. The study was registered with clinicaltrials.gov with the initial release date 1/18/16 (NCT02881996). There was no funding source.

Participants

The study population consisted of children from 2 to 17 years old that were found to have perforated appendicitis. Those found to have nonperforated appendicitis and/or a normal appendix at the time of the operation were excluded. Those with history of chronic pain, known underlying liver disorders, and allergy to pain medication in protocol and non-English speaking patients were also excluded.

Sample Size

Power calculations were based on the known average length of time on PCA of 3.5 days with a standard deviation of 1.5 with goal time off PCA of 2.5 days in the treatment group. These data points were gathered from our previous randomized trial. Using these numbers with an α = 0.05 and power of 0.9, we calculated a sample size of 80 patients with 40 patients in each study arm. We intended to recruit 100 patients and have 80 randomized.

Assignment

A computer-generated individual unit of randomization was utilized in a nonstratified sequence in blocks of four. Consent was obtained by pediatric surgery fellows and pediatric surgery research fellows. After consent for study enrollment was obtained, a sequentially numbered opaque envelope was accessed to obtain the next allotment. The attending surgeons and anesthesiologists did not obtain consent and were blind to the allotment throughout the enrollment process. All data were analyzed on an intention-to-treat basis, and patients remained in their assigned group. The rounding teams were not blinded to randomization as the both the surgical and anesthesiology teams participated in the pain management during the course of hospitalization.

Protocol

Preoperatively, patients were given as needed intravenous fentanyl, morphine, or hydromorphone boluses for pain control. A balanced sevoflurane-based general anesthetic with tracheal intubation was utilized. Induction was performed with weight appropriate doses of propofol, rocuronium, fentanyl, and lidocaine. Additional opioids were given intraoperatively based on response to surgical stimulation, and dexmedetomidine was commonly given to mitigate potential emergence delirium or agitation. Intraoperative anesthetic regimen included wound infiltration with local anesthetic.

Postoperatively, all patients were placed on a morphine or hydromorphone PCA pump, which was managed by the anesthesia department. Morphine was dosed 20 mcg/kg with 8-minute lockout along with a 20 mcg/kg/h continuous infusion. Hydromorphone was dosed at 4 mcg/kg with 8-minute lockout along with a 4 mcg/kg/h continuous infusion. All continuous infusions were left for at least 24 hours and then were switched to nightly infusions (10 p.m.–8 a.m.) at the discretion of the anesthesiologist. As per our existing protocol, IIV ketorolac (0.5 mg/kg every 6 hours) was provided for 5 days. Ketorolac was held if urine output was below 0.5 cc/h.

Those patients in the treatment arm received their first dose of IVA 3 hours after their initial dose of ketorolac. IVA was dosed at 10 mg/kg and scheduled every 6 hours for a total of 3 days staggered in between doses of ketorolac. If the PCA is discontinued prior to 3 days, the IVA was also discontinued as patients were then transitioned to oral analgesics.

Patients in the control arm were managed with scheduled ketorolac and PCA pump without IVA. Patients in the control group only received by mouth or per rectum acetaminophen as needed for treatment of fevers. PCA pumps were discontinued once the patient had a return of bowel function and were tolerating oral intake. The surgical and anesthesia team collaborated and mutually decided when to discontinue the PCA.

European Journal of Pediatric Surgery Vol. 29 No. 2/2019
Patients were transitioned to our standard postoperative pain regimen of 0.1 mg/kg oral oxycodone/acetaminophen 5/325 every 4 hours as needed.

The patient’s pain control was measured by utilizing the Visual Analogue Scale (VAS) twice daily. For patients less than 7 years old, the validated Wong–Baker FACES score was used. The scores were obtained by the pediatric surgery fellow and/or pediatric surgery research fellow, who were appropriately trained in administering and interpreting these scoring tools.

Data Collection
A single individual who had no role in the clinical care, collected all data prospectively. Demographics collected included age, weight, height, body mass index (BMI), and gender. Prehospital characteristics, operative characteristics, complications, radiographic findings, and hospital charges were also recorded. Hospital outcomes include length of stay, time to return of bowel function, time to completion of oral medications, time to initiation of diet, narcotic associated adverse effects (nausea, emesis, respiratory depression), and overall hospital cost. Total PCA narcotic doses were converted to morphine equivalent dose.

Statistics
All data were analyzed on intention-to-treat basis. Descriptive statistics including means, standard deviations, medians, interquartile ranges, counts, and percentages were analyzed. Pearson’s chi-square and Fisher’s exact tests were used for categorical variables. Continuous variables were compared using Student’s two-sample t-test and Mann–Whitney U-test. Hodges–Lehmann 95% confidence intervals (CIs) for location shift were used for those variables with p-values determined by Mann–Whitney U-Test. Statistical significance was set at p < 0.05, and all reported p-values are two-tailed. Statistical analysis was performed using IBM SPSS Statistics (version 23, IBM Corp., Armonk, New York, United States).

Results
From July, 2014 to November, 2015, 90 children were randomized to either receive IVA or no IVA (►Fig. 1). During this time frame, 99 patients were identified to have perforated appendicitis. All families were approached for enrollment in the study. Nine declined to participate. Forty-five were allocated to the IVA arm and 45 to the no IVA arm. Six patients were excluded from the IVA arm. One patient did not have perforated appendicitis, five patients deviated from protocol. Two patients from the non-IVA arm were excluded due to protocol deviation. A total of 82 patients (39 in the IVA arm and 43 in the non-IVA arm) were analyzed.

Pain Characteristics
There was no statistically significant difference in the time on the PCA (p = 0.27; 95% CI: −28.9 to 8.2) and the time to transition from the PCA to oral pain medications for children given IVA compared with children not receiving IVA (p = 0.27; 95% CI: −29.7 to 8.4). Both groups showed no difference in the amount of intravenous narcotic pain medicine given and pain scores. There was no difference in the amount of oral narcotics between both groups (p = 0.76; 95% CI: −1.0 to 1.0). The PCA alone group received significantly more oral acetaminophen compared with the IVA group (p = 0.01; 95% CI: 1914.4–2514.8) (►Table 1).

Patient Characteristics
Males accounted for 64 and 70% in each study arm. They were similar in age and BMI. There was no significant statistical difference in the admission white blood cell count, and duration of symptoms (►Table 2).

Postoperative Outcomes
Those given IVA had a statistically significant longer operative time compared with patients with a PCA alone (p < 0.01;
During the hospital stay, there was no significant statistical difference in temperature on POD#1; however, children with PCA alone had significantly higher temperatures on POD#2 to 5. There was no statistical significant difference in time to initial enteral feeding ($p = 0.28$; 95% CI: −5.27 to 17.69), time to return of bowel function ($p = 0.49$; 95% CI: −17.45 to 8.37), and number of antiemetic medications given ($p = 0.95$; 95% CI: −1.0 to 1.0). There was no statistically significant difference with the incidence of postoperative abscess ($p = 0.55$) and the time to abscess

### Table 1 Pain characteristics

<table>
<thead>
<tr>
<th></th>
<th>IVA and PCA (n = 39)</th>
<th>PCA alone (n = 43)</th>
<th>p-Value</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time on PCA (h)</td>
<td>76.4 ± 32.5</td>
<td>86.7 ± 49.3</td>
<td>0.27</td>
<td>−28.9 to 8.2</td>
</tr>
<tr>
<td>PCA delivered (mg/kg/day)$^a$$^b$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>POD #1</td>
<td>2.0 (1.0, 4.5)</td>
<td>1.9 (0.8, 3.5)</td>
<td>0.35</td>
<td>−0.4 to 1.3</td>
</tr>
<tr>
<td>POD #2</td>
<td>9.5 (5.0, 14.9)</td>
<td>8.4 (4.0, 16.7)</td>
<td>0.64</td>
<td>−2.4 to 3.4</td>
</tr>
<tr>
<td>POD #3</td>
<td>9.1 (3.8, 15.5)</td>
<td>10.5 (3.1, 19.5)</td>
<td>0.63</td>
<td>−4.6 to 2.7</td>
</tr>
<tr>
<td>POD #4</td>
<td>6.9 (1.4, 13.6)</td>
<td>10.9 (5.3, 18.3)</td>
<td>0.06</td>
<td>−8.9 to 0.2</td>
</tr>
<tr>
<td>POD #5</td>
<td>5.9 (1.5, 11.4)</td>
<td>8.6 (7.3, 24.5)</td>
<td>0.20</td>
<td>−8.7 to 2.0</td>
</tr>
<tr>
<td>VAS score</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>POD #1 a.m.</td>
<td>2.5 ± 1.9</td>
<td>2.3 ± 2.0</td>
<td>0.64</td>
<td></td>
</tr>
<tr>
<td>POD #1 p.m.</td>
<td>3.2 ± 2.3</td>
<td>2.6 ± 2.5</td>
<td>0.30</td>
<td></td>
</tr>
<tr>
<td>POD #2 a.m.</td>
<td>2.1 ± 2.1</td>
<td>2.8 ± 1.9</td>
<td>0.13</td>
<td></td>
</tr>
<tr>
<td>POD #2 p.m.</td>
<td>2.4 ± 2.1</td>
<td>2.4 ± 2.0</td>
<td>0.95</td>
<td></td>
</tr>
<tr>
<td>POD #3 a.m.</td>
<td>2.0 ± 2.2</td>
<td>2.7 ± 2.5</td>
<td>0.30</td>
<td></td>
</tr>
<tr>
<td>POD #3 p.m.</td>
<td>2.3 ± 2.1</td>
<td>2.3 ± 1.9</td>
<td>0.93</td>
<td></td>
</tr>
<tr>
<td>Transition to oral pain medications (h)</td>
<td>78.6 ± 33.6</td>
<td>89.2 ± 49.7</td>
<td>0.27</td>
<td>−29.7 to 8.4</td>
</tr>
<tr>
<td>Total no. of oral narcotics (doses)$^b$</td>
<td>2 (1, 3)</td>
<td>2 (1, 4)</td>
<td>0.76</td>
<td>−1.0 to 1.0</td>
</tr>
<tr>
<td>Total no. of oral acetaminophen (doses)$^b$</td>
<td>0.5 (0, 2)</td>
<td>2 (0, 5)</td>
<td>0.01</td>
<td>−2.0 to 0</td>
</tr>
<tr>
<td>Total pain medication charges$^b$</td>
<td>$3,395.67 (2,842.23, 3,964.51)$</td>
<td>$1,127.03 (825.05, 1,481.32)$</td>
<td>&lt;0.01</td>
<td>1914.4–2514.8</td>
</tr>
</tbody>
</table>

### Table 2 Patient characteristics

<table>
<thead>
<tr>
<th></th>
<th>IVA and PCA (n = 39)</th>
<th>PCA alone (n = 43)</th>
<th>p-Value</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male, no. (%)</td>
<td>25 (64)</td>
<td>30 (70)</td>
<td>0.59</td>
<td></td>
</tr>
<tr>
<td>Female, no. (%)</td>
<td>14 (36)</td>
<td>13 (30)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (y)</td>
<td>10.9 ± 4.0</td>
<td>9.6 ± 4.0</td>
<td>0.14</td>
<td>−0.43 to 3.09</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>19.3 ± 5.5</td>
<td>18.7 ± 5.4</td>
<td>0.61</td>
<td>−1.78 to 3.02</td>
</tr>
<tr>
<td>Admission WBC count ($10^3$ mcL)</td>
<td>18.0 ± 4.2</td>
<td>18.6 ± 6.9</td>
<td>0.64</td>
<td>−3.24 to 2.00</td>
</tr>
<tr>
<td>Duration of symptoms (d)</td>
<td>3.9 ± 2.7</td>
<td>2.9 ± 1.8</td>
<td>0.07</td>
<td>−0.06 to 1.95</td>
</tr>
</tbody>
</table>

Abbreviations: BMI, body mass index; CI, confidence interval; IVA, intravenous acetaminophen; PCA, patient-controlled analgesia; POD, postoperative day; VAS, visual analog scale.

$^a$Reported as morphine equivalents.

$^b$Reported as median (IQR).
formation \((p = 0.28; \text{95\% CI: } -3.29 \text{ to } 18.41)\). The non-IVA group did stay close to a half day longer postoperatively compared with the IVA group; however, this was not a statistically significant difference \((p = 0.35; \text{95\% CI: } -1.2 \text{ to } 0.3)\). There was no difference in the hospital charges between the two groups \((p = 0.42; \text{95\% CI: } -3762.19 \text{ to } 9263.39)\) \((\text{Table 3})\).

### Discussion

This is the first randomized control trial evaluating the use of IVA after laparoscopic appendectomy for perforated appendicitis. In our study, there was no statistically significant difference in the time off the PCA, and transition time to oral pain medications. The IVA was not effective in reducing parenteral and oral narcotic requirements during their hospital stay and patients reported similar pain scores. There was an increased medication cost for the IVA group; however, there was no statistically significant difference in overall hospital costs between the groups due to the large denominator.

Children with generalized peritonitis due to their appendicitis have been shown to have more pain, consume more opioids, and have an increased PCA demand in comparison to those without peritonitis.\(^{18}\) The increase in opioid use and abuse in the United States along with lowering the incidence of opioid-related adverse effects has led to an emphasis in optimizing nonnarcotic pain management especially after surgery.\(^{19-21}\) In the adult population, IVA has been shown to reduce the need for opioids, lowering hospital costs, and decreasing postoperative pain visits to the emergency department.\(^{22-24}\) In children, recent systemic reviews have shown an opioid sparing effect for IVA after major abdominal surgery.\(^{25,26}\) While there has been randomized trials for postoperative pain control after open appendectomy, there is limited evidence identifying a postoperative pain regimen for laparoscopic appendectomy that can minimize the use of opioids.\(^{16,18,27}\) In fact, PCAs are currentlystill being used for postoperative pain management after appendectomies, though current evidence suggests that the need for a PCA may be declining.\(^{28,29}\)

We felt that utilizing PCAs was crucial for providing a background environment to study the impact of scheduled IVA because each patient would have similar background noise depending on the threshold of the patient, parent, nurse, and house staff for demanding medications. The PCA bypasses these thresholds and allows to detect difference in demands and delivered, in which we did not see a difference.

A possible reason that we did not see a significant difference in the time off the PCA and decrease in narcotic demands and house staff for demanding medications. The alternative, utilizing as needed medications would introduce too much background noise depending on the threshold of the patient, parent, nurse, and house staff for demanding medications. The PCA bypasses these thresholds and allows to detect difference in demands and delivered, in which we did not see a difference.

### Table 3  Postoperative outcomes

|                      | IVA and PCA  
|----------------------|--------------|
|                      | \((n = 39)\)  
|                      | PCA alone \(n = 43\)  
|                      | \(p\)-Value\| 95% CI\n| Operative time (min) | 45.9 ± 21.1\| 34.8 ± 10.5\| <0.01\| 3.96–18.40\n| Maximum temperature \((\degree C)\)\(a\) | 38.0 (37.6, 39.2)\| 38.6 (37.9, 39.5)\| 0.11\| –0.8 to 0.1\n| POD #1 | 37.8 (37.4, 38.8)\| 38.7 (37.8, 39.3)\| 0.01\| –1.1 to \((-0.1)\)\n| POD #3 | 37.4 (37.1, 37.9)\| 37.8 (37.3, 38.7)\| 0.02\| –0.7 to \((-0.1)\)\n| POD #4 | 37.5 (37.2, 37.8)\| 37.9 (37.5, 38.4)\| 0.03\| –0.6 to 0.0\n| POD #5 | 37.3 (37.1, 37.5)\| 37.9 (37.5, 38.2)\| <0.01\| –0.8 to \((-0.3)\)\n| Time to initial enteral feeding (h) | 42.9 ± 32.0\| 36.6 ± 19.2\| 0.28\| –5.27 to 17.69\n| Time to return of bowel function (h) | 30.6 ± 29.8\| 35.1 ± 29.8\| 0.49\| –17.45 to 8.37\n| Total # of antiemetic medication given (doses)\(a\) | 1.5 (0, 4.5)\| 1 (0, 4)\| 0.95\| –1.0 to 1.0\n| Abscess formation, no. (%) | 7 (18)\| 10 (23)\| 0.55\n| Time to abscess formation (d) | 7.2 ± 1.6\| 8.3 ± 2.1\| 0.28\| –3.29 to 18.41\n| Postoperative length of stay (d)\(a\) | 3.9 (3.1, 5.9)\| 4.5 (3.1, 6.1)\| 0.35\| –1.2 to 0.3\n| Total hospital charges\(a\) | $46,947.13 (41,336.43, 62,803.70)\| $46,593 (39,230.48, 55,614.07)\| 0.42\| –3,762.19 to 9,263.39\n
Abbreviations: CI, confidence interval; IQR, interquartile range; IVA, intravenous acetaminophen; PCA, patient-controlled analgesia; POD, postoperative day.

\(a\)Reported as median (IQR).
fevers; therefore, any benefit from IV acetaminophen could have been mitigated by the fact that the non IV acetaminophen group was still receiving doses of acetaminophen.

The limitations include our narcotic regimen was managed by our anesthesia department, therefore the pain regimen and type of narcotics was based on a nonstandardized preference by each anesthesiologist. Since they were not blinded to which patients were receiving IVA, they may have been biased toward the pain regimen they recommended. Our preoperative pain regimen was not standardized, and therefore, there may have been variability in early postoperative pain management and scores that we cannot quantify. Patient were supposed to be transition off the PCA once having bowel function and tolerating diet; yet, transition to oral medication occurred 36 hours in the IVA group and 53 hours in the non-IVA group after starting enteral feeds and with established bowel function. This may have been due to variability in management between surgery and anesthesia which caused the delay in transition. Lastly, our study was powered to find significance with a full day difference in transitioning off the PCA. The half-day difference was not statistically significant, given that we powered our study for a one-day difference.

Conclusion

Children given IVA showed no difference in the transition time off the PCA and to oral pain medications after laparoscopic appendectomy for perforated appendicitis. Children still used the same amount of narcotics with no change in pain perceptions. Further studies are needed to evaluate the role of IV acetaminophen in opioid sparing pain regimens after abdominal surgery in children.

Conflict of Interest

None.

Acknowledgment

The authors thank Ashley Sherman, MA, for her work with analyzing the results.

References

24 McNicol ED, Ferguson MC, Haroutounian S, Carr DB, Schumann R. Single dose intravenous paracetamol or intravenous propacetamol...


